Dr Diane Harper, a lead researcher in the development of the humanpapilloma virus vaccine
HPV
Vaccine Researcher Drops Bombshell At NVIC Conference
Dr
Diane Harper, a lead researcher in the development of the
humanpapilloma virus vaccine
Dr Diane Harper, lead researcher in the development of two human papilloma virus vaccines, Gardasil and Cervarix, said the controversial drugs will do little to reduce cervical cancer rates and are being recommended for girls as young as nine. During a 2007 interview with KPC News.com, she said giving the vaccine to girls as young as 11 years-old “is a great big public health experiment.” Dr Harper dropped an even bigger bombshell on the audience when she announced that, “There have been no efficacy trials in girls under 15 years.” Dr Harper, director of the Gynecologic Cancer Prevention Research Group at the University of Missouri, made these remarks during an address at the NVIC 4th International Public Conference on Vaccination which took place in Reston, Virginia on Oct. 2-4.
Susan Brinkmann, The Philadelphia Bulletin
Related Links:
*
Dr
Diane Harper On HPV Vaccines
Ramesh Shankar, Mumbai,
PHARMABIZ.com
* What
Has The HPV Cancer Vaccine Done To Our Girls?
Daniel Foggo &
Rosie Millard, The Sunday Times
* Girl
Brain Damaged After Cancer Vaccine
Andrew Moran, Digital
Journal
* The
New Journalism - Challenging The Status Quo
Jane Bryant,
National Vaccine Information Center Conference Speech, United States
of America
Experts
Warn - Serious Adverse Events From Untested Swine Flu
Vaccines
Programs
for vaccination against the new influenza A/H1N1 targeting many
hundred million citizens in Europe and the USA are to be launched in
the fall of this year. The European nations are opting for inclusion
of MF59, the adjuvant contained in an alternative seasonal flu
vaccine, or the related adjuvant AS03 that is contained in a recently
developed H5N1 vaccine. Evidence from animal experiments in
conjunction with clinical epidemiological data indicates that, quite
irrespective of cause, stimulation of the immune system may
accelerate atherogenesis. Application of adjuvanted flu vaccines to
individuals at risk may therefore aggravate the course of underlying
atherosclerotic vessel disease with all the clinical consequences.
The same may hold true for other widespread diseases that are
propelled by deregulated immune mechanisms. Safety trials conducted
to date have not specifically taken these possible side effects into
account, and unexpected serious adverse effect s thus may follow in
the wake of a general vaccination program.
Bhakdi S, Lackner K, Doerr HW, Med Microbiol Immunol.DOI 10.1007/s00430-009-0130-9
Fourth
Person Dies In Sweden From Swine Flu Shot
The
news that a fourth person has died after taking the "swine flu"
jab in Sweden is focussing attention on the failure of the Swedish
Medical Products Agency (MPA) to halt the "swine flu"
programme even as reports of serious side effects flood in. The EMEA
derives three-quarters of its funding from pharmaceutical companies.
The "swine flu" jab has been authorised for use only on
condition that governments and companies implement
"post-authorisation" studies to check it is safe and
effective. However, the MPA in Sweden appears to have limited its
role in collecting data on death and damage to spontaneous reports
from doctors and patients.
Editorial, The Flu Case
Related Links:
*
Pregnant
Women In Britain Given Untested Pandemrix Swine Flu Vaccine
Thomas
Moore, Sky News
* GSK’s
Pandemrix Swine Flu Vaccine - Pandora's Box Release
Lara,
Health Advocate
* Child
Vaccines Overload - Swine Flu Shot Untested
Beezy Marsh, Daily
Mail